Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Enanta Pharmaceuticals is a biotechnology business based in the US. Enanta Pharmaceuticals stocks (ENTA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $71.5 – an increase of 10.45% over the previous week. Enanta Pharmaceuticals employs 155 staff and has a trailing 12-month revenue of around $91.6 million.
Finder's Pick for
Beginners
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
| Latest market close | $45.01 |
|---|---|
| 52-week range | $37.59 - $102.00 |
| 50-day moving average | $51.74 |
| 200-day moving average | $65.73 |
| Wall St. target price | $66.63 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.52 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $45.01 from 2022-06-24
| 1 week (2022-06-21) | 11.69% |
|---|---|
| 1 month (2022-05-27) | 14.04% |
| 3 months (2022-03-24) | -33.58% |
| 6 months (2021-12-28) | -39.99% |
| 1 year (2021-06-28) | 0.07% |
|---|---|
| 2 years (2020-06-26) | -9.40% |
| 3 years (2019-06-28) | 84.38 |
| 5 years (2017-06-28) | 21.48% |
Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.8 million.
The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $91.6 million |
|---|---|
| Gross profit TTM | $97.1 million |
| Return on assets TTM | -18.84% |
| Return on equity TTM | -28.27% |
| Profit margin | -122.68% |
| Book value | $17.39 |
| Market capitalisation | $932.3 million |
TTM: trailing 12 months
We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $37.59 up to $102. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.6742. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).
Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. .
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…
Here are some investment ideas that could do well despite rising interest rates.
Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Everything we know about the Onfolio Holdings IPO plus information on how to buy in.
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
